Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy**
Miguel A. Quiñones, MD, FACC*,
Barry H. Greenberg, MD, FACC ,
Helen A. Kopelen, RDMS*   || ¶,
Chris Koilpillai, MD,
Marian C. Limacher, MD, FACC,
Daniel M. Shindler, MD, FACC||,
Brent J. Shelton, PhD¶,
Debra H. Weiner, MPH* || ¶ for the SOLVD Investigators**
* Divisions of Cardiology, Baylor College of Medicine, Houston, Texas, USA
Oregon Health Sciences University, Portland, Oregon, USA
Dalhousie University, Halifax, Nova Scotia, Canada
University of Florida College of Medicine, Gainesville, Florida, USA
|| Robert Wood Johnson School of Medicine, Piscataway, New Jersey, USA
¶ Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA
View larger version (15K):
[in a new window]
|
Figure 1 Kaplan-Meier unadjusted survival curves (expressed as cumulative 1-year mortality) observed in patients with LVEF at or above vs. below 35%.
|
|
View larger version (15K):
[in a new window]
|
Figure 2 Kaplan-Meier unadjusted survival curves (expressed as cumulative 1-year mortality) observed in patients with LV mass at or above vs. below the mean value of 298 g.
|
|
View larger version (23K):
[in a new window]
|
Figure 3 Kaplan-Meier unadjusted survival curves (expressed as cumulative 1-year mortality) observed in patients grouped according to LV mass and EF. The log-rank statistic p value (0.0014) compares nonparametrically the event rate experience of the four groups.
|
|
|
